Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOLA trial of cabozantinib plus lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors
2019-004506-10Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and lanreotide in Gastroenteropancreatic Carcinoid Tumor and apudoma (NET), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Safety and tolerability. Started Jan 2021; status: active.
02
Drugs
cabozantiniblanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumorapudoma (NET)
Beyond the preview
Go deeper on 2019-004506-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004506-10.